Analysis of inflammatory immune correlation of the coagulation spectrum, PT, FBG, FDP, D-D in autoimmune diseases
Coagulation spectrum, PT, FBG, FDP, D-D in RA and pSS
Abstract
Objective: To investigate the expression of coagulation markers and their correlations with immunological function and inflammation in patients with autoimmune diseases (sjogren's syndrome and rheumatoid arthritis).
Methods: A total of 183 patients were selected for the study: 61 RA patients who made up the RA group were admitted to our hospital between December 2023 and December 2024, 61 pSS patients composed the pSS group, and 61 normal physical examinees who were in the physical examination center of our hospital during the same period composed the control group. Baseline clinical indicators of patients in each group before treatment were collected, including the plasma prothrombin time (PT), international normalized ratio (INR), thrombin time (TT), plasma fibrinogen (FBG), partial thromboplastin time (APTT), fibrinogen degradation products (FDP), and plasma D-dimer (D-D).
Results: The expression levels of PT, FBG, TT, FDP and DD in the RA group, the pSS group and the normal group were significantly different. The expression levels of PT, FBG, FDP and D-D in the RA group were all greater than those in the pSS group and the control group. The expression level of PT in the pSS group was greater than that in the control group. The expression levels of PT, FBG, FDP and D-D in the RA group were all greater than those in the pSS group and the control group. The expression level of PT in the pSS group was greater than that in the control group. Analysis of the receiver operating characteristic (ROC) curve showed that, in contrast to those in the normal group, the area under the curve (AUC) of PT in the RA group were 0.638, the AUC of FBG was 0.899, the AUC of FDP was 0.866, and the AUC of D-D was 0.919. The AUC of the combined diagnosis of RA by coagulation indicators was greater than that of the individual detection of each indicator. Compared with that in the normal group, the AUC of PT in the pSS group was 0.618 (P=0.025), and the AUC of TT was 0.645 (P=0.006). The AUC of the combined diagnosis of coagulation indicators for pSS was greater than that of the individual detection of each indicator. Higher D-D in RA patients was significantly linked to higher hs-CRP, CCP, and RF, while higher FBG was significantly linked to higher hs-CRP, ESR, RF, and CCP. Correlation analysis revealed that in the RA group, PT, INR, FBG, FDP, and D-D were positively correlated with CRP and ESR, whereas TT was negatively correlated with CRP and ESR. FBG, FDP and D-D in the pSS group were positively correlated with CRP and ESR. In addition, the coagulation indicators in the RA group were positively correlated with the immune indicators, whereas in the pSS group, they were partially negatively correlated, both of which were significant. In addition, the coagulation indicators in the RA group were positively correlated with the immune indicators, whereas in the pSS group, they were partially negatively correlated, both of which were significant. In patients with pSS, FBG and FDP are positively correlated with hs-CRP, and APTT and FBG are positively correlated with the ESR.
Conclusion: Compared with those of pSS, PT, FBG, FDP and D-D have greater reference value for the early diagnosis of RA and the determination of disease severity and can be used as important predictive indicators for the confirmed diagnosis of RA.
References
2.Wang F, Liu J, Wang Y, Sun Y, Wen J, He M. Correlation Analysis of Coagulation and Platelet Parameters with Clinical Outcomes in Rheumatoid Arthritis Patients and the Interventional Effect of Jianpi Huashi Tongluo Formula - Xinfeng Capsule: A Post Hoc Analysis Based on an Randomized Controlled Trial. Drug Des Devel Ther. 2025 Apr 29;19:3477-3495. doi: 10.2147/DDDT.S512338. PMID: 40322027; PMCID: PMC12049676.
3.Zhao H, Li L, Wang HY, Ding L, Wang Y, Liu X, Tian S, Wang Y. Efficacy analysis of clinical serological indicators in the diagnosis of postoperative periprosthetic joint infection in patients with rheumatoid arthritis or osteoarthritis. Int Orthop. 2024 Aug;48(8):1945-1952. doi: 10.1007/s00264-024-06171-y. Epub 2024 Apr 6. PMID: 38581467.
4.Hassan FA, Elkassas NEM, El-Bltagy EA, Mohamed MS, Mobarez S, Salim IH, Abdel-Aal MM. Dietary zinc-chitosan nanoparticles addition influences on growth performance, apparent total tract digestibility, carcass indices, and immune function in weaned rabbits. Anim Biotechnol. 2023 Dec;34(9):4819-4827. doi: 10.1080/10495398.2023.2197467. Epub 2023 Apr 13. PMID: 37051844.
5.Zhang J, Chen J, Yang X, Han J, Chen X, Fan Y, Zheng H. Novel risk prediction models, involving coagulation, thromboelastography, stress response, and immune function indicators, for deep vein thrombosis after radical resection of cervical cancer and ovarian cancer. J Obstet Gynecol. 2023 Dec;43(1):2204162. doi: 10.1080/01443615.2023.2204162. PMID: 37089113.
6.Liu Y, Zhang A, Guo N, Hao Q, Li F. A pattern recognition receptor ficolin from Portunus trituberculatus (Ptficolin) regulating immune defense and hemolymph coagulation. Int J Biol Macromol. 2022 Nov 30;221:558-572. doi: 10.1016/j.ijbiomac.2022.09.041. Epub 2022 Sep 9. PMID: 36089094.
7.Chen W, Zhao X, Lu Y, Wang H, Wang X, Wang Y, Liang C, Jia Z, Ma W. Clinical significance, molecular characterization, and immune microenvironment analysis of coagulation-related genes in clear cell renal cell carcinoma. Cancer Innov. 2024 Jan 7;3(1):e105. doi: 10.1002/cai2.105. PMID: 38948537; PMCID: PMC11212306.
8.Li J, Zhang F, Lan X, Li F, Tan C, Cao W. Novel risk prediction models for deep vein thrombosis after thoracotomy and thoracoscopic lung cancer resections, involving coagulation and immune function. Open Life Sci. 2023 May 23;18(1):20220617. doi: 10.1515/biol-2022-0617. PMID: 37250843; PMCID: PMC10224613.
9.Zhang X, Huang H. Comparison of the efficacy and impact on coagulation function of different rituximab dosage regimens in the treatment of membranous nephropathy. Am J Transl Res. 2025 Mar 15;17(3):1974-1984. doi: 10.62347/WQAB1378. PMID: 40226032; PMCID: PMC11982884.
10.Tao J, Wang L, Gu Z, Zhang L. Effect of Bortezomib Treatment in Multiple Myeloma on Blood Coagulation Function, Renal Function, Immune Function, and the NF-κB Pathway-Associated Indicators. Br J Hosp Med (Lond). 2025 Mar 26;86(3):1-15. doi: 10.12968/hmed.2024.0701. PMID: 40135312.
11.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
12.Wu T, Wu S, Li M, Zhang J. Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations. Ann Pharmacother. 2024 Jan;58(1):28-36. doi: 10.1177/10600280231158929. Epub 2023 Apr 26. PMID: 37125735.
13.Fang X, Fu W, Xu L, Qiu Y. Analysis of the diagnostic value of coagulation markers and coagulation function indices on the occurrence of DIC in sepsis and its prognosis. Allergol Immunopathol (Madr). 2024 Sep 1;52(5):65-72. doi: 10.15586/aei.v52i5.1119. PMID: 39278853.
14.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
15.Yang H, Yuan Y, Shi L, Yang Y, Zhu Y, Chen Y. Enhanced diagnostic capabilities of thromboelastography coupled with standard coagulation indices for predicting perioperative thrombosis in older individuals with hip fractures : TEG coupled with standard coagulation indices for predicting thrombosis in hip fractures. J Orthop Surg Res. 2024 Dec 24;19(1):870. doi: 10.1186/s13018-024-05386-4. PMID: 39719587; PMCID: PMC11667881.
16.Radenkovic S, Bleukx S, Engelhardt N, Eklund E, Mercimek-Andrews S, Edmondson AC, Morava E. Coagulation abnormalities and vascular complications are common in PGM1-CDG. Mol Genet Metab. 2024 Aug;142(4):108530. doi: 10.1016/j.ymgme.2024.108530. Epub 2024 Jul 2. PMID: 38968673.
17.Wang Y, Li Y, Zhou Y, Gao Y, Zhao L. Guanxinning Tablet Alleviates Post-Ischemic Stroke Injury Via Regulating Complement and Coagulation Cascades Pathway and Inflammatory Network Mobilization. Drug Des Devel Ther. 2024 Sep 18;18:4183-4202. doi: 10.2147/DDDT.S479881. PMID: 39308695; PMCID: PMC11416781.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
19.Zhou L, Chai JH, Zhang Y, Jing XJ, Kong XW, Liang J, Xia YG. TMT-Based Proteomics Reveal the Mechanism of Action of Amygdalin against Rheumatoid Arthritis in a Rat Model through Regulation of Complement and Coagulation Cascades. Molecules. 2023 Oct 17;28(20):7126. doi: 10.3390/molecules28207126. PMID: 37894605; PMCID: PMC10609517.
20.Wang F, Liu J, Wang Y, Sun Y, Wen J, He M. Correlation Analysis of Coagulation and Platelet Parameters with Clinical Outcomes in Rheumatoid Arthritis Patients and the Interventional Effect of Jianpi Huashi Tongluo Formula - Xinfeng Capsule: A Post Hoc Analysis Based on an Randomized Controlled Trial. Drug Des Devel Ther. 2025 Apr 29;19:3477-3495. doi: 10.2147/DDDT.S512338. PMID: 40322027; PMCID: PMC12049676.
21.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
22.Cao G, Zhang S, Wang Y, Xu H, Quan S, Cai L, Feng W, Yao J, Tan H, Pei F. The efficacy and safety of tranexamic acid in rheumatoid arthritis patients undergoing simultaneous bilateral total knee arthroplasty: a multicenter retrospective study. BMC Musculoskelet Disord. 2023 May 15;24(1):379. doi: 10.1186/s12891-023-06485-9. PMID: 37189066; PMCID: PMC10184364.
23.Yang Y, Zhang L, Zhao X, Li J, Chen Q, Gao Y, Yan J. Evaluation of the prognostic value of coagulation function and cerebral hemodynamic changes in acute ischemic stroke patients with rheumatoid arthritis. Ann Biol Clin (Paris). 2025 May 22;83(2):185-94. doi: 10.1684/abc.2025.1965. PMID: 40341111.
24.Giachi A, Cugno M, Gualtierotti R. Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis. Front Cardiovasc Med. 2022 Oct 24;9:1012661. doi: 10.3389/fcvm.2022.1012661. PMID: 36352850; PMCID: PMC9637771.
25.Fukami Y, Koike H, Iijima M, Mouri N, Nishi R, Katsuno M. Role of complement components in vasculitic neuropathy associated with systemic lupus erythematosus and rheumatoid arthritis. Muscle Nerve. 2022 Aug;66(2):175-182. doi: 10.1002/mus.27636. Epub 2022 Jun 1. PMID: 35581952.
26.Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.
27.Tsai YC, Chang HC, Chiou MJ, Luo SF, Kuo CF. Fetal-neonatal and maternal pregnancy outcomes in women with rheumatoid arthritis: a population-based cohort study. BMJ Open. 2022 Oct 26;12(10):e059203. doi: 10.1136/bmjopen-2021-059203. PMID: 36288841; PMCID: PMC9615975.
28.Yu J, Hu C, Dai Z, Xu J, Zhang L, Deng H, Xu Y, Zhao L, Li M, Liu L, Zhang M, Huang J, Wu L, Chen G. Dipeptidyl peptidase 4 as a potential serum biomarker for disease activity and treatment response in rheumatoid arthritis. Int Immunopharmacol. 2023 Jun;119:110203. doi: 10.1016/j.intimp.2023.110203. Epub 2023 Apr 24. PMID: 37094543.
29.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
30.Lin YY, Huang CC, Ko CY, Tsai CH, Chang JW, Achudhan D, Tang CH. Omentin-1 modulates interleukin expression and macrophage polarization: Implications for rheumatoid arthritis therapy. Int Immunopharmacol. 2025 Mar 6;149:114205. doi: 10.1016/j.intimp.2025.114205. Epub 2025 Feb 4. PMID: 39908806.
31.Aripova N, Duryee MJ, England BR, Hunter CD, Mordeson JE, Ryan EM, Daubach EC, Romberger DJ, Thiele GM, Mikuls TR. Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis. Front Immunol. 2023 Aug 16;14:1203548. doi: 10.3389/fimmu.2023.1203548. PMID: 37654483; PMCID: PMC10467288.
32.Yao M, Huang X, Guo Y, Zhao JV, Liu Z. Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: Genome-wide cross trait analysis and bidirectional Mendelian randomization study. J Med Virol. 2023 Feb;95(2):e28570. doi: 10.1002/jmv.28570. PMID: 36762574.
33.Lee JJY, Bernatsky S, Kwong JC, Li Q, Kwok TSH, Widdifield J. Safety and Health Care Use Following COVID-19 Vaccination Among Adults With Rheumatoid Arthritis: A Population-Based Self-Controlled Case Series Analysis. J Rheumatol. 2023 Oct 1:jrheum.2023-0355. doi: 10.3899/jrheum.2023-0355. Epub ahead of print. PMID: 37778762.
34.Hansildaar R, Raadsen R, Gerritsen M, Nagy M, Dijkshoorn B, Spronk HMH, Ten Cate H, Nurmohamed MT. Comparative Analysis of Coagulation Activation in Rheumatoid Arthritis Patients Treated With TNF Inhibitors Versus JAK Inhibitors: A Longitudinal Study. J Clin Rheumatol. 2024 Dec 1;30(8):e166-e171. doi: 10.1097/RHU.0000000000002136. Epub 2024 Sep 30. PMID: 39342416.
35.Kratz EM, Kacperczyk M, Kokot I, Piwowar A, Konopska B, Sokolik R, Korman L. Glycosylation Pattern of Serum Clusterin in Psoriatic Arthritis and Rheumatoid Arthritis-The Search for New Diagnostic Glycomarkers. Int J Mol Sci. 2024 Dec 5;25(23):13060. doi: 10.3390/ijms252313060. PMID: 39684771; PMCID: PMC11642323.
Copyright (c) 2025 Yinghong Zhong, Xiao He, Xiufeng Geng, Heng Huang, Zhixian Zhang, Xuezhong Ren, Hong Chen
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.